General Information:

Id: 11,827 (click here to show other Interactions for entry)
Diseases: COVID-19
Homo sapiens
Reference: Hoffmann M et al.(2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Cell 181: 271-280.e8 [PMID: 32142651]

Interaction Information:

Comment SARS-CoV can use the endosomal cysteine proteases cathepsin B and L (CatB/L) and the serineprotease TMPRSS2 for S protein priming in cell lines, and inhibition of both proteases is required for robust blockade of viral entry. However, only TMPRSS2 activity is essential for viral spread and pathogenesis in the infected host whereas CatB/L activity is dispensable. This study shows that SARS-CoV-2 can use TMPRSS2 for S protein priming and camostat mesylate, an inhibitor of TMPRSS2, blocks SARS-CoV-2 infection of lung cells.
Formal Description
Interaction-ID: 116877

drug/chemical compound

Camostat mesilate

decreases_activity of



in lung cells